Immunodeficient (B-NDG) Mice_Biocytogen Pharmaceuticals (Beijing) Co., Ltd._Biocytogen,drug development,antibody discovery

Please input keywords

Product No	Product	Application area
110586	B-NDG mice	Immune reconstitution, CDX, transplantation, drug evaluation
110586	B-NDG mice-PDX	Immune reconstitution, CDX, transplantation, drug evaluation
110587	B-NDG nude mice	Human immune system reconstitution
110601	B-NDG B2m KO mice plus	Reduce PBMC reconstitution GVHD response and prolong experimental window
110600	B-NDG hIL15 mice	Promote human NK cell differentiation
110599	B-NDG HLA-A2.1 mice	Vaccine study
110596	B-NDG hIL6 mice	Promotes human monocyte differentiation
110590	B-NDG hTHPO mice	Without irradiation, it reduces the damage caused by irradiation to mice
110604	B-NDG hSIRPA mice	Maintain progenitor capacity
120612	B-NDG hIL7/hIL15 mice	Promote differentiation of human T cells and NK cells
110603	B-NDG hSIRPA/hCD47 mice	Evaluation of pharmacodynamic and toxicity of CD47, SIRPA targeted drugs
120609	B-NDG hCSF1/hTHPO mice	Promote differentiation of human myeloid cells without irradiation
112864	huHSC-B-NDG hIL6 mice	Promote differentiation of human monocyte-macrophage
112480	huHSC-B-NDG hTHPO mice	Irradiation is not required to avoid damage to mice caused by irradiation
112479	huHSC-B-NDG MGMT3 mice	Promote differentiation of human myeloid cells；Irradiation is not required to avoid damage to mice caused by irradiation
112865	huHSC-B-NDG HLA-A2.1 mice	To verify the efficacy of HLA-A2.1 restricted vaccines；Promote the development of human CD8+ T cells
112451	B-NDG hB2M/HLA-A11.1 mice	To verify the efficacy of HLA-A11.1 restricted vaccines and antibody-based therapies；Promote the development of human CD8+ T cells
112560	B-NDG hB2M/HLA-A24.2 mice	To verify the efficacy of HLA-A24.2 restricted vaccines and antibody-based therapies；Promote the development of human CD8+ T cells
112450	B-NDG hB2M/HLA-A3.1 mice	To verify the efficacy of HLA-A3.1 restricted vaccines and antibody-based therapies；Promote the development of human CD8+ T cells
112256	B-NDG H2-K1/H2-D1 KO mice	No MHC class I molecule expression; Reduce GVHD and prolong the experimental window period; Improve the accuracy of efficacy verification
111982	B-NDG hALB mice	Used for pharmacological or pharmacokinetic studies of drugs that utilize albumin to extend their half-life
112653	B-NDG hIL15, FcγR KO mice	Promote differentiation of human NK cells；No mouse Fc receptor function
112478	huHSC-B-NDG hIL15 mice	Promote differentiation of human NK cells
112482	huNK-B-NDG hIL15 mice	Promote differentiation of human NK cells
112449	B-NDG hB2M/HLA-A2.1 mice plus	To verify the efficacy of HLA-A2.1 restricted vaccines and antibody-based therapies；Promote the development of human CD8+ T cells
112470	huHSC-B-NDG mice	Human immune system reconstitution, mainly T cells and B cells；reconstitutionl Human-derived cell or tissue engraftmentl Tumor research；Human disease model studyl Efficacy and toxicity verification for
112469	hPBMC-B-NDG mice	Human T cell reconstitution；Human-derived cell or tissue engraftment；Tumor researchl Human disease model study；Efficacy and toxicity verification for human targeted drugs
110593	B-NDG hGM-CSF mice	Promote differentiation of human myeloid cells；For mating with other humanized mice that promote myeloid cell differentiation to obtain multi-humanized mice
110598	B-NDG hairless mice	Hairless, easy to measure tumor
110597	B-NDG hIL7 mice	Promote differentiation of human lymphoid cells
110595	B-NDG H2-Ab1 KO mice	No MHC class II molecule expression; Reduce GVHD and prolong the experimental window period；Improve the accuracy of efficacy verification
111882	B-NDG MGMT3 mice	Promote differentiation of human myeloid cells；Irradiation is not required to avoid damage to mice caused by irradiatio
111895	B-NDG MHC I/II DKO mice plus	No MHC class I/II molecule expression；Reduce GVHD and prolong the experimental window period；Improve the accuracy of efficacy verification
111922	B-NDG hFcRn mice	PK (NDG background can reduce ADA)
111856	B-NDG B2m plus/hIL15 mice	Human immune system reconstitution
110605	B-NDG Hc mice	Antibody CDC function study

バイオサイトジェンの本社は北京市にあり、江蘇省海門、アメリカのボストン、上海に子会社を保有しております。総従業員数は約1200人で、100%子会社であるEucure Biopharmaを通じて臨床開発を遂行しています。詳しくは下記のリンクをクリックして何でもお問い合わせください。

お問い合わせ